Dolphin
Senior Member (Voting Rights)
From MassME newsletter
https://massmecfs.org/newsletters/906-2024-10-october-newsletter
OMF's Life Improvement Trial (LIFT) Has Begun
OMF is starting a double-blind, placebo-controlled clinical trial of low dose naltrexone (LDN) and pyridostigmine (Mestinon) on functional capacity, physiological response, and symptoms of ME/CFS.
Both drugs have shown promising results in some people and this study is designed to measure the response and determine who responds. These results can be used to develop individualized treatment plans in the future.
Study participants must live within 100 miles of Brigham and Women's Hospital at Harvard Medical School (Boston, MA). Participants will be recruited through OMF's StudyME registry and among patients in the Harvard Medical School system. Sign up for the StudyME registry here.
https://massmecfs.org/newsletters/906-2024-10-october-newsletter
OMF's Life Improvement Trial (LIFT) Has Begun
OMF is starting a double-blind, placebo-controlled clinical trial of low dose naltrexone (LDN) and pyridostigmine (Mestinon) on functional capacity, physiological response, and symptoms of ME/CFS.
Both drugs have shown promising results in some people and this study is designed to measure the response and determine who responds. These results can be used to develop individualized treatment plans in the future.
Study participants must live within 100 miles of Brigham and Women's Hospital at Harvard Medical School (Boston, MA). Participants will be recruited through OMF's StudyME registry and among patients in the Harvard Medical School system. Sign up for the StudyME registry here.
